Related Experiment Videos
[Gene therapy in malignant mesothelioma]
Arif Osman Tokat1, Hakan Kutlay
1Thoracic Surgery, Ankara Research and Educational Hospital, 06600 Kurtuluş, Ankara, Turkey.
Tuberkuloz Ve Toraks
|May 15, 2004
Summary
Malignant mesothelioma, a rare cancer linked to asbestos, lacks standard treatments. Gene therapy, particularly using the herpes simplex virus (HSV) tk gene, shows promise for treating this deadly pleural disease.
Area of Science:
- Oncology
- Genetics
- Cell Biology
Context:
- Malignant mesothelioma is a rare, aggressive cancer originating from pleural mesothelial cells.
- Asbestos exposure is a primary etiological factor.
- Current treatments lack standardization and efficacy.
Purpose:
- To explore the potential of gene therapy as a novel treatment modality for malignant mesothelioma.
- To investigate the feasibility of using gene modification to enhance treatment outcomes.
Summary:
- Gene therapy involves altering malignant cells' genetic structure to increase sensitivity to antiviral drugs.
- The herpes simplex virus (HSV) thymidine kinase (tk) gene is a commonly studied gene for this purpose.
- Malignant mesothelioma's primary cause of mortality is local tumor spread, making localized therapies like gene therapy potentially effective.
Impact:
- Gene therapy offers a promising, targeted approach for malignant mesothelioma, addressing the limitations of current therapeutic strategies.
- This approach could improve patient outcomes by directly targeting cancer cells within the pleural space.